Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs Crowdstrike Holdings Inc (CRWD) Price & Performance

Boston Scientific CorporationTrade
Crowdstrike Holdings IncTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs Crowdstrike Holdings Inc — how do they compare? Boston Scientific Corporation trades at $51.28 (market cap $74.19B), while Crowdstrike Holdings Inc trades at $221.4 (market cap $225.95B). The key difference: Crowdstrike Holdings Inc is far larger — about 3× Boston Scientific Corporation's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.

BSXCRWD
Market Cap
$74.19B$225.95B
Sector
HealthTechnology
52-Week High
$108.14$225.16
52-Week Low
$42.63$87.56
Enterprise Value
$86.27B$222.22B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

Crowdstrike Holdings Inc

CrowdStrike (CRWD) trades at $221.85, down 1.47% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue growth remains strong, reaching $3.95 billion in 2025, though net income margins are negative. Recent news highlights leadership in cybersecurity and AI-driven threat detection, with the stock up 106% over six months. A 1:4 stock split occurred on July 2, 2026.

The stock offers growth exposure to cybersecurity demand, supported by analyst optimism and platform consolidation, but carries high valuation multiples and profitability risks. Upside depends on sustained revenue expansion and margin improvement, while volatility and competitive pressures pose challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About Crowdstrike Holdings Inc

CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.

Read more on CRWD